Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Megumi Ikemori

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
Yakugaku Zasshi : Journal of the Pharmaceutical Society of Japan|March 1, 2021
[Consideration on Industry-Academia Partnering in Drug Discovery Development: Based on a Questionnaire Survey of Pharmaceutical Companies and Academia]Kaori Iida, Takahiko Yano, Megumi Ikemori, et al.
Journal of Chemical Information and Modeling|July 27, 2012
Docking simulation study and kinase selectivity of f152A1 and its analogsMegumi Ikemori-Kawada, Atsushi Inoue, Masaki Goto, et al.
Journal of Chemical Information and Modeling|December 10, 2009
Conformational analyses and MO studies of f152A1 and its analogues as potent protein kinase inhibitorsMegumi Ikemori-Kawada, Takatoshi Kawai, Masaki Goto, et al.
Anticancer Research|May 31, 2024
Antitumor Activity of Tasurgratinib as an Orally Available FGFR1-3 Inhibitor in Cholangiocarcinoma Models With FGFR2-fusionSatoshi Kawano, Megumi Ikemori Kawada, Sayo Fukushima, et al.
Cancer Medicine|May 8, 2018
Lenvatinib inhibits angiogenesis and tumor fibroblast growth factor signaling pathways in human hepatocellular carcinoma modelsMasahiro Matsuki, Taisuke Hoshi, Yuji Yamamoto, et al.
Molecular Cancer Therapeutics|January 23, 2014
Novel ATP-competitive MEK inhibitor E6201 is effective against vemurafenib-resistant melanoma harboring the MEK1-C121S mutation in a preclinical modelYusuke Narita, Kiyoshi Okamoto, Megumi Ikemori Kawada, et al.
ACS Medicinal Chemistry Letters|January 16, 2015
Distinct binding mode of multikinase inhibitor lenvatinib revealed by biochemical characterizationKiyoshi Okamoto, Megumi Ikemori-Kawada, Anja Jestel, et al.
Mutagenesis|May 13, 2022
Optimizing machine-learning models for mutagenicity prediction through better feature selectionNicolas K Shinada, Naoki Koyama, Megumi Ikemori, et al.
NPJ Systems Biology and Applications|December 18, 2023
Asking the right questions for mutagenicity prediction from BioMedical textSathwik Acharya, Nicolas K Shinada, Naoki Koyama, et al.
Bioorganic & Medicinal Chemistry Letters|April 30, 2010
Discovery of an in vitro and in vivo potent resorcylic lactone analog of LL-Z1640-2 as anti-inflammatory lead, IIYongchun Shen, Hong Du, Makoto Kotake, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Yakugaku Zasshi : Journal of the Pharmaceutical Society of Japan|March 1, 2021
[Consideration on Industry-Academia Partnering in Drug Discovery Development: Based on a Questionnaire Survey of Pharmaceutical Companies and Academia]Kaori Iida, Takahiko Yano, Megumi Ikemori, et al.
Journal of Chemical Information and Modeling|July 27, 2012
Docking simulation study and kinase selectivity of f152A1 and its analogsMegumi Ikemori-Kawada, Atsushi Inoue, Masaki Goto, et al.
Journal of Chemical Information and Modeling|December 10, 2009
Conformational analyses and MO studies of f152A1 and its analogues as potent protein kinase inhibitorsMegumi Ikemori-Kawada, Takatoshi Kawai, Masaki Goto, et al.
Anticancer Research|May 31, 2024
Antitumor Activity of Tasurgratinib as an Orally Available FGFR1-3 Inhibitor in Cholangiocarcinoma Models With FGFR2-fusionSatoshi Kawano, Megumi Ikemori Kawada, Sayo Fukushima, et al.
Cancer Medicine|May 8, 2018
Lenvatinib inhibits angiogenesis and tumor fibroblast growth factor signaling pathways in human hepatocellular carcinoma modelsMasahiro Matsuki, Taisuke Hoshi, Yuji Yamamoto, et al.
Molecular Cancer Therapeutics|January 23, 2014
Novel ATP-competitive MEK inhibitor E6201 is effective against vemurafenib-resistant melanoma harboring the MEK1-C121S mutation in a preclinical modelYusuke Narita, Kiyoshi Okamoto, Megumi Ikemori Kawada, et al.
ACS Medicinal Chemistry Letters|January 16, 2015
Distinct binding mode of multikinase inhibitor lenvatinib revealed by biochemical characterizationKiyoshi Okamoto, Megumi Ikemori-Kawada, Anja Jestel, et al.
Mutagenesis|May 13, 2022
Optimizing machine-learning models for mutagenicity prediction through better feature selectionNicolas K Shinada, Naoki Koyama, Megumi Ikemori, et al.
NPJ Systems Biology and Applications|December 18, 2023
Asking the right questions for mutagenicity prediction from BioMedical textSathwik Acharya, Nicolas K Shinada, Naoki Koyama, et al.
Bioorganic & Medicinal Chemistry Letters|April 30, 2010
Discovery of an in vitro and in vivo potent resorcylic lactone analog of LL-Z1640-2 as anti-inflammatory lead, IIYongchun Shen, Hong Du, Makoto Kotake, et al.
Pageof 2